February 08, 2022
Weil advised Sanofi in its up to $1.225 billion acquisition of Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform Pro-XTENTM to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer. The transaction closed on February 08, 2022.
The Weil team that advised Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Matthew Gilroy, Mergers & Acquisitions counsel Kimberly Thibault and Mergers & Acquisitions associates Sarah Grinshtein, Michael Block and Aryi Kohandel-Shirazi. The team also included Tax Head Joseph Pari; Tax partner Graham Magill; Tax counsel Blake Bitter; Tax associate Musa Jemal; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits partner Amanda Rosenblum; Executive Compensation & Benefits associate Manleen Singh (Admitted in Illinois Only); Technology & IP Transactions partner Michael Epstein; Technology & IP Transactions Co-Head Jeffrey Osterman; Technology & IP Transactions/Privacy associates Catherine Kim, Hui Li, Meggin Bednarczyk and Justin Yun; Environmental Head Annemargaret Connolly; Regulatory Transactions partner Kevin Sullivan; Regulatory Transactions counsel John O’Loughlin; Regulatory Transactions associate Ariel Fliman; Antitrust Head Steven Newborn; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Antitrust associate Jarui Wang; Securities Litigation partner Robert Carangelo; and Employment Litigation associate Nicole Jibrine.